Monoclonal antibodies (mAbs) follow distinct pharmacokinetic principles from small molecule drugs. Their large molecular size (approximately 150 kDa for a full IgG), proteinaceous nature, and specific interactions with neonatal Fc receptors (FcRn) and their therapeutic targets produce an ADME (absorption, distribution, metabolism, excretion) profile that is largely independent of the hepatic CYP450 (cytochrome P450) enzyme system, creating a strikingly different drug interaction landscape compared to the targeted small molecules covered in Modules 01 and 02.
Absorption and Route of Administration. The vast majority of therapeutic mAbs are administered intravenously (IV), bypassing the GI (gastrointestinal) tract entirely because antibodies are degraded by gastrointestinal proteases and have negligible oral bioavailability. Subcutaneous (SC) formulations are available for selected agents including trastuzumab (with recombinant human hyaluronidase), daratumumab, and rituximab; subcutaneous delivery achieves bioavailability of approximately 70-80% relative to IV, through convective flow into the lymphatic system followed by systemic absorption. SC formulations extend injection time from hours to minutes, improving patient convenience and reducing chair time, but require validated pharmacokinetic bridging studies to confirm therapeutic equivalence. Intramuscular (IM) delivery is not used for therapeutic antibodies. Some antibodies have been reformulated for inhalation (not currently approved for oncology indications) or intrathecal administration for CNS (central nervous system) disease.
Distribution and Volume of Distribution. Full-length IgG1 antibodies have a volume of distribution (Vd) of approximately 3-8 liters, reflecting primarily plasma and interstitial fluid distribution with very limited intracellular penetration; they do not cross the blood-brain barrier under normal conditions.1 This restricted distribution contrasts sharply with small molecule drugs, which typically have Vd values in the hundreds to thousands of liters, reflecting extensive tissue partitioning. The limited CNS penetration of conventional mAbs is a significant pharmacologic constraint in diseases with CNS manifestations (e.g., Her2-positive breast cancer with brain metastases), driving the development of smaller antibody fragments (scFv [single-chain variable fragment], bispecific T-cell engagers), bispecific antibodies with transferrin receptor-mediated CNS delivery, and small molecule TKIs (tyrosine kinase inhibitors) with CNS penetration as covered in Module 01. Antibody-drug conjugates (ADCs) generally share the large-molecule distribution limitations of their parent antibodies but can deliver cytotoxic payloads with intracellular activity after internalization.
FcRn Recycling and Extended Half-Life. The characteristic long half-lives of therapeutic IgG antibodies (typically 14-21 days) are governed by the neonatal Fc receptor (FcRn), which binds IgG in the acidic environment of endosomes (pH 6.0) after pinocytosis, protecting it from lysosomal degradation, and releases it back into the circulation at physiological pH (7.4).1 This FcRn-mediated recycling is saturable; at very high antibody concentrations, FcRn becomes occupied and proteolytic degradation increases, producing nonlinear pharmacokinetics where clearance increases disproportionately at elevated doses. Albumin undergoes the same FcRn-mediated recycling, which is why albumin-bound drugs also have extended half-lives. FcRn is expressed throughout the body including in placental syncytiotrophoblasts, which is the mechanism by which maternal IgG crosses the placenta; this also means therapeutic mAbs can cross the placenta after the first trimester and potentially affect fetal immune development, a consideration of clinical importance for mAb prescribing in pregnancy.
Target-Mediated Drug Disposition. Many therapeutic antibodies exhibit target-mediated drug disposition (TMDD), a pharmacokinetic phenomenon in which binding to the high-affinity pharmacologic target constitutes a significant elimination pathway, particularly at low drug concentrations when target-mediated clearance is not yet saturated.1 TMDD produces nonlinear pharmacokinetics: at sub-saturating concentrations, the antibody is rapidly cleared by receptor-mediated endocytosis of the antibody-target complex; at concentrations above target saturation, clearance follows the slower FcRn-governed route and half-life extends. This explains why some mAbs show substantially shorter effective half-lives at low doses and require loading doses to rapidly achieve target-saturating concentrations. Examples include cetuximab (EGFR [epidermal growth factor receptor]-mediated clearance) and trastuzumab (HER2 [human epidermal growth factor receptor 2]-mediated endocytosis).
Metabolism and Elimination. Unlike small molecule drugs, therapeutic mAbs are not substantially metabolized by hepatic CYP (cytochrome P450) enzymes. They are instead catabolized throughout the body by ubiquitous proteolytic degradation to amino acids, which are reutilized in protein synthesis. This means that hepatic impairment has minimal pharmacokinetic impact on most mAbs, and dose adjustments for liver disease are generally not required. Renal excretion of intact antibody is negligible given the large molecular size (above the glomerular filtration threshold of approximately 60-70 kDa); however, some smaller antibody fragments do undergo renal clearance. The clinical implication is that the extensive drug-drug interaction profiles of small molecule oncology agents are largely absent with mAbs; CYP-based interactions, P-glycoprotein (P-gp) effects, and renal transporters are not relevant pharmacokinetic considerations for full-length IgG antibodies.1
Immunogenicity and Anti-Drug Antibodies. Because mAbs are proteins, they can elicit immune responses generating anti-drug antibodies (ADAs) that may neutralize the therapeutic antibody, accelerate its clearance, or cause hypersensitivity reactions. The risk of immunogenicity has been progressively reduced through antibody engineering: murine antibodies (suffix -omab) have the highest immunogenicity; chimeric antibodies (suffix -ximab; approximately 25-35% human sequence) are moderately immunogenic; humanized antibodies (suffix -zumab; approximately 90-95% human) have lower immunogenicity; and fully human antibodies (suffix -umab; 100% human sequence) have the lowest immunogenicity.2 However, even fully human antibodies can elicit ADAs against idiotypic (antigen-binding region) epitopes. Pre-medication with corticosteroids (dexamethasone or methylprednisolone), antihistamines (diphenhydramine), and acetaminophen before mAb infusions reduces but does not eliminate infusion-related reactions, most of which are cytokine release-driven rather than true IgE-mediated anaphylaxis. True anaphylaxis is rare but requires epinephrine and emergency management; subsequent rechallenge is generally contraindicated.
The INN (International Nonproprietary Name) suffix encodes the antibody source and target class. Source: -o- (mouse), -xi- (chimeric), -zu- (humanized), -u- (fully human). Target class: -tu- (tumor), -li- (immunological), -ci- (cardiovascular), -vi- (viral). Examples: ritux-i-mab (chimeric, immunological); trastuz-u-mab (humanized, tumor); panitum-u-mab (fully human, tumor); ipilim-u-mab (fully human, immunological). The newest nomenclature system (INN 2021 revision) no longer requires the substem encoding, so newer antibodies (e.g., cemiplimab, dostarlimab) use simplified suffixes. Bispecific antibodies typically use -bi- in the stem.
The anti-HER2 (human epidermal growth factor receptor 2) and anti-VEGF (vascular endothelial growth factor) antibodies represent two of the most consequential classes in oncology pharmacology. Their mechanisms, toxicity profiles, and drug interaction principles are frequently tested because they generate high-stakes clinical decisions around cardiac monitoring, blood pressure management, surgical timing, and sequential drug administration.
Trastuzumab: Mechanism and HER2 Biology. Trastuzumab is a humanized IgG1 monoclonal antibody that binds domain IV of the extracellular domain of HER2 (also designated ErbB2 or c-erbB-2), a transmembrane receptor tyrosine kinase of the ErbB family.3 HER2 has no known direct ligand but is the preferred dimerization partner for other ErbB family members (EGFR [epidermal growth factor receptor]/ErbB1, HER3/ErbB3, HER4/ErbB4); overexpression of HER2 amplifies signaling from all ErbB family heterodimers. HER2 amplification or overexpression (defined as IHC [immunohistochemistry] 3+ or FISH [fluorescence in situ hybridization] ratio of HER2:CEP17 [chromosome 17 centromere probe] of 2 or greater) occurs in approximately 15-20% of breast cancers and 10-15% of gastric/gastroesophageal junction (GEJ) cancers.
The mechanisms of trastuzumab action include: (1) steric blockade of HER2 extracellular domain cleavage (preventing release of the constitutively active p95-HER2 fragment); (2) inhibition of downstream PI3K (phosphoinositide 3-kinase)/AKT (protein kinase B) and MAPK (mitogen-activated protein kinase) signaling; (3) antibody-dependent cellular cytotoxicity (ADCC) via Fc-region interaction with NK (natural killer) cells and macrophages; and (4) possible interference with HER2 homodimerization.
Trastuzumab Cardiotoxicity: Mechanism and Monitoring. The most important clinical toxicity of trastuzumab is cardiomyopathy with reduction in LVEF (left ventricular ejection fraction), occurring in approximately 3-7% of patients as monotherapy and substantially higher rates (27-34% in early trials) when combined with anthracyclines.3 The mechanism differs in kind from anthracycline cardiotoxicity: anthracycline cardiotoxicity results from irreversible free radical-mediated damage to cardiomyocyte mitochondria and DNA (deoxyribonucleic acid), is dose-dependent, cumulative, and largely irreversible; trastuzumab cardiotoxicity results from inhibition of HER2 (human epidermal growth factor receptor 2)/HER4 (human epidermal growth factor receptor 4)-mediated cardiac repair signaling (ErbB2 signaling in cardiomyocytes promotes stress-response hypertrophy and protects against anthracycline-induced damage), is generally not dose-dependent, and is largely reversible upon drug discontinuation. This mechanistic distinction has two critical clinical consequences: (1) trastuzumab cardiotoxicity is managed by holding the drug (typically 4-8 weeks) and reassessing LVEF, with re-initiation in most cases after recovery; (2) the combination of trastuzumab with anthracyclines is not given concurrently but sequentially (anthracycline-based chemotherapy followed by trastuzumab after completion), since the combination produces unacceptably high rates of severe cardiomyopathy when given simultaneously. Baseline LVEF assessment by echocardiography or MUGA (multigated acquisition) scan is mandatory; repeat every 3 months during therapy and 6 weeks after completion.
Trastuzumab is held for LVEF below 50% or a decrease of 16 percentage points or more; it is permanently discontinued for persistent LVEF decline after two hold-and-reassess cycles.
Pertuzumab and HER2 Dimerization Inhibition. Pertuzumab is a humanized IgG1 mAb that binds domain II of the HER2 extracellular domain (a different epitope from trastuzumab, which binds domain IV), inhibiting HER2 dimerization with other ErbB family members, particularly the HER2 (human epidermal growth factor receptor 2)-HER3 (human epidermal growth factor receptor 3) heterodimer that drives the most potent downstream oncogenic signaling.3 Pertuzumab is used in combination with trastuzumab and docetaxel as first-line therapy in HER2-positive metastatic breast cancer (CLEOPATRA trial) and in the neoadjuvant and adjuvant settings in early-stage HER2-positive breast cancer. The combination of pertuzumab plus trastuzumab provides dual HER2 blockade at distinct extracellular domain epitopes, producing superior outcomes compared to trastuzumab monotherapy. The cardiac monitoring requirements for pertuzumab are identical to trastuzumab; pertuzumab itself does not add substantially to cardiac risk when added to trastuzumab but carries a risk of fetal harm and embryo-fetal toxicity (it must not be used during pregnancy and requires effective contraception). Diarrhea is a common pertuzumab-related adverse effect, occurring in approximately 67% of patients (grade 3 or higher: 7-8%), managed with loperamide and dose reduction.
Bevacizumab: Anti-VEGF Mechanism and ADME (Absorption, Distribution, Metabolism, Excretion). Bevacizumab is a humanized IgG1 mAb that binds all isoforms of VEGF-A (vascular endothelial growth factor A), preventing VEGF-A from binding its receptors VEGFR-1 (vascular endothelial growth factor receptor 1) and VEGFR-2 (vascular endothelial growth factor receptor 2) on endothelial cells, thereby inhibiting tumor angiogenesis.4 Bevacizumab is approved in combination with chemotherapy for metastatic colorectal cancer (first and second line), non-squamous non-small cell lung cancer (NSCLC), recurrent glioblastoma, metastatic renal cell carcinoma (with interferon-alfa), and metastatic cervical cancer. The half-life of bevacizumab is approximately 20 days, consistent with FcRn-recycled IgG; it is given every 2-3 weeks. Unlike small molecule VEGFR (VEGF receptor) TKIs (tyrosine kinase inhibitors), bevacizumab does not undergo hepatic CYP (cytochrome P450) metabolism and has no clinically significant CYP-based drug interactions. However, bevacizumab inhibits all circulating VEGF-A isoforms, including those involved in physiological vascular maintenance, which accounts for its class toxicity profile.
Bevacizumab Toxicity: Hypertension, Proteinuria, and Wound Healing. The toxicity profile of bevacizumab is mechanistically derived from inhibiting physiological VEGF-A signaling in normal vasculature and tissues.4 Hypertension occurs in approximately 23-35% of patients (grade 3 or higher in 8-18%) and results from VEGF-A withdrawal in the endothelium, reducing nitric oxide (NO) synthesis and prostacyclin (PGI2) production, leading to vasoconstriction; it is managed with standard antihypertensive agents (dihydropyridine calcium channel blockers, ACE (angiotensin-converting enzyme) inhibitors, or ARBs [angiotensin receptor blockers] preferred; avoid diltiazem/verapamil if patient is also on CYP3A4 (cytochrome P450 3A4)-metabolized oncology drugs). Proteinuria results from VEGF-A-dependent maintenance of glomerular podocyte function; urinalysis before each cycle is standard, with 24-hour urine protein quantification for dipstick 2+ or higher (bevacizumab is held for proteinuria exceeding 2 g/24 hours and permanently discontinued for nephrotic-range proteinuria exceeding 3.5 g/24 hours).
Bevacizumab Wound Healing and Bowel Perforation. Wound healing impairment is an important safety concern: VEGF-A is required for new blood vessel formation in healing wounds, and bevacizumab impairs this process, creating risk of wound dehiscence, anastomotic leak, and chronic non-healing wounds. Bevacizumab must be held for at least 28 days before elective surgery and not resumed until at least 28 days after surgery with complete wound healing confirmed; bevacizumab is held for 28 days before and after elective procedures. Bowel perforation (0.9-2.4%), an unpredictable but potentially fatal complication, results from compromise of tumor-invading bowel vasculature and impaired repair of microscopic perforations; risk is higher in patients with colorectal cancer, prior abdominal radiation, and bowel obstruction. RPLS (reversible posterior leukoencephalopathy syndrome), now more commonly termed PRES (posterior reversible encephalopathy syndrome), occurs in less than 0.5% of patients, manifesting with headache, altered mental status, visual disturbances, and seizures; MRI (magnetic resonance imaging) shows characteristic posterior white matter edema; bevacizumab is permanently discontinued.
Concurrent administration of trastuzumab with anthracyclines (doxorubicin, epirubicin) is contraindicated due to unacceptable rates of symptomatic heart failure (27% in the pivotal HER2 trial). Standard practice: complete anthracycline-based chemotherapy first (e.g., AC [doxorubicin-cyclophosphamide] for 4 cycles), then start trastuzumab after the last anthracycline dose. The sequential approach reduces symptomatic cardiac events to approximately 2-4%. Always confirm that anthracycline therapy is complete before initiating any HER2-directed antibody therapy. Pertuzumab shares this requirement.
This section covers four mechanistically distinct mAb targets with distinct companion diagnostic requirements, toxicity profiles, and clinical decision rules that appear frequently in T3/T4 (higher-order clinical vignette) scenarios: EGFR (epidermal growth factor receptor) in colorectal cancer, CD20 (cluster of differentiation 20, a B-cell surface antigen) in B-cell lymphomas and autoimmune disease, CD38 (cyclic ADP-ribose hydrolase) in multiple myeloma, and RANKL (receptor activator of NF-kB ligand) in bone metastases.
Cetuximab and Panitumumab: Anti-EGFR Antibodies. Cetuximab is a chimeric IgG1 mAb and panitumumab is a fully human IgG2 mAb; both bind the extracellular domain of EGFR (epidermal growth factor receptor), blocking ligand binding and receptor activation, and are approved for EGFR-expressing metastatic colorectal cancer (mCRC [metastatic colorectal cancer]) and head and neck squamous cell carcinoma (HNSCC [head and neck squamous cell carcinoma]).5 A prerequisite for anti-EGFR therapy in mCRC is wild-type RAS (rat sarcoma viral proto-oncogene) status: patients with any RAS mutation (KRAS [Kirsten rat sarcoma viral proto-oncogene] exon 2, 3, or 4; NRAS [neuroblastoma RAS viral proto-oncogene] exon 2, 3, or 4) derive no benefit from anti-EGFR therapy because constitutively activated RAS bypasses EGFR-mediated signaling, making EGFR inhibition ineffective as a strategy to suppress downstream RAS/MAPK (mitogen-activated protein kinase) pathway activation. Extended RAS testing (beyond KRAS exon 2 codons 12/13) is now mandatory before prescribing; BRAF (v-raf murine sarcoma viral oncogene homolog B) V600E (valine-to-glutamate at codon 600) mutation also predicts lack of benefit from single-agent anti-EGFR therapy in mCRC (though encorafenib plus cetuximab is the BRAF V600E-mutant mCRC standard of care).
Anti-EGFR antibodies are used in left-sided (but not right-sided) mCRC only, as right-sided tumors have higher rates of RAS (rat sarcoma viral proto-oncogene)/BRAF mutations and worse outcomes with anti-EGFR therapy regardless of mutation status.
Anti-EGFR Toxicity: Acneiform Rash. Acneiform rash occurs in approximately 80% of patients on anti-EGFR antibodies; its severity positively correlates with response and survival.5 Prophylactic oral tetracyclines (doxycycline or minocycline) reduce rash severity and are standard practice.
Hypomagnesemia and Alpha-Gal Reactions. A distinctive toxicity of anti-EGFR antibodies not seen with EGFR TKIs is hypomagnesemia, occurring in approximately 35-40% of patients and reaching grade 3 or higher in 5-10%. The mechanism is EGFR-dependent magnesium reabsorption in the distal convoluted tubule (DCT) via the TRPM6 (transient receptor potential melastatin 6) magnesium channel; EGFR blockade reduces TRPM6 expression, impairing active magnesium reabsorption and causing renal magnesium wasting. Hypomagnesemia requires regular serum magnesium monitoring (before each cycle) and supplementation, and can be severe and symptomatic (neuromuscular irritability, cardiac arrhythmias). A unique safety concern with cetuximab is a high rate of severe (grade 3 or higher) infusion reactions (approximately 3% overall but up to 22% in the southeastern United States), many of which are IgE-mediated true hypersensitivity reactions caused by pre-existing IgE antibodies against galactose-alpha-1,3-galactose (alpha-gal), a sugar epitope present on the cetuximab Fc region derived from its mouse cell line production and found in mammalian meat; the geographic clustering reflects tick-bite sensitization to alpha-gal in areas where lone-star ticks are endemic. Panitumumab, produced in a non-murine cell line, lacks the alpha-gal epitope and has a substantially lower severe infusion reaction rate.
Rituximab: Anti-CD20 Antibody. Rituximab is a chimeric IgG1 mAb targeting CD20 (membrane-spanning 4A family member 1), a B-cell surface antigen expressed from the pre-B cell stage through the mature B cell stage but absent on plasma cells (which explains why plasma cell-derived immunoglobulin production is preserved after rituximab treatment).6 CD20 is expressed on approximately 95% of B-cell non-Hodgkin lymphomas (NHL [non-Hodgkin lymphoma]) and CLL (chronic lymphocytic leukemia). Rituximab depletes B cells through multiple complementary mechanisms: ADCC (antibody-dependent cellular cytotoxicity) via Fc-mediated NK (natural killer) cell and macrophage recruitment; CDC (complement-dependent cytotoxicity) via C1q binding and complement cascade activation; and direct induction of apoptosis. Beyond oncology, rituximab is approved for rheumatoid arthritis, granulomatosis with polyangiitis, and other autoimmune diseases. Its half-life is approximately 22 days; B-cell depletion persists for 6-9 months after a standard course. ADME (absorption, distribution, metabolism, excretion): rituximab is a large IgG1 antibody with the typical large-molecule pharmacokinetics described in Section 1; clearance is partially target-mediated (via CD20-expressing B-cell populations).
Rituximab Safety: HBV (Hepatitis B Virus) Reactivation and PML (Progressive Multifocal Leukoencephalopathy) Risk. Two serious infectious complications are associated with rituximab-mediated B-cell depletion and immune suppression.6 HBV (hepatitis B virus) reactivation is a potentially fatal complication occurring in HBsAg (hepatitis B surface antigen)-positive patients and, at lower rates, in patients who are HBsAg-negative but HBcAb (hepatitis B core antibody)-positive (indicating prior resolved infection with occult viral persistence). B-cell depletion removes the immune control of occult HBV, allowing viral replication to surge; clinical reactivation can manifest as hepatitis flare, fulminant hepatic failure, or death. All patients must be screened for HBsAg and HBcAb before rituximab initiation: HBsAg-positive patients require prophylactic antiviral therapy (entecavir or tenofovir, preferred over lamivudine due to lower resistance rates) started before rituximab and continued for at least 12-18 months after completion; HBcAb-positive/HBsAg-negative patients should also receive antiviral prophylaxis or undergo close monitoring with HBV DNA (deoxyribonucleic acid) quantification at 1-3 month intervals (institution-specific protocols vary).
PML Risk With Rituximab. PML (progressive multifocal leukoencephalopathy), caused by JC (John Cunningham) virus reactivation in the CNS (central nervous system), is a rare (approximately 1 in 25,000 patients) but devastating complication of rituximab in patients receiving prolonged or repeated courses in autoimmune diseases and lymphoma; it presents with subacute progressive neurological deficits, dementia, and ataxia; brain MRI (magnetic resonance imaging) shows characteristic white matter lesions without mass effect; CSF (cerebrospinal fluid) JC virus PCR (polymerase chain reaction) confirms the diagnosis; no proven effective treatment exists and mortality or severe disability approaches 50-80%.
Obinutuzumab: Type II Anti-CD20 Antibody. Obinutuzumab is a fully humanized, glycoengineered type II anti-CD20 IgG1 mAb that differs mechanistically from rituximab (a type I anti-CD20 antibody) in two key respects: it does not induce CD20 translocation into lipid rafts (which is required for type I antibody CDC activation) and therefore has enhanced direct cell death induction, and its glycoengineered Fc region has approximately 50-fold enhanced affinity for FcgammaRIII (Fc gamma receptor III) on NK cells and macrophages, producing superior ADCC compared to rituximab.6 Obinutuzumab is approved for CLL (with chlorambucil, first-line), follicular lymphoma (in combination and as monotherapy maintenance), and marginal zone lymphoma. Infusion-related reactions are more frequent and severe with obinutuzumab than rituximab, particularly with the first infusion; step-wise infusion rate escalation and mandatory pre-medication are required.
Daratumumab: Anti-CD38 in Multiple Myeloma. Daratumumab is a fully human IgG1 kappa mAb targeting CD38 (cyclic ADP-ribose hydrolase), a type II transmembrane glycoprotein expressed at high levels on myeloma cells and at low levels on normal hematopoietic cells including T cells, B cells, NK (natural killer) cells, and red blood cells (RBCs [red blood cells]).7 Daratumumab depletes myeloma cells through ADCC, CDC, ADCP (antibody-dependent cellular phagocytosis), and direct apoptosis, and additionally depletes CD38-expressing regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs [myeloid-derived suppressor cells]), potentially enhancing anti-tumor immunity. It is approved in multiple myeloma in combinations including daratumumab-bortezomib-melphalan-prednisone (first-line transplant-ineligible), daratumumab-bortezomib-thalidomide-dexamethasone (first-line transplant-eligible), daratumumab-lenalidomide-dexamethasone (relapsed/refractory), and daratumumab-carfilzomib-dexamethasone (relapsed/refractory). A clinically critical consequence of daratumumab’s binding to CD38 on RBCs is interference with pre-transfusion testing: daratumumab coats patient RBCs, causing pan-reactive false-positive indirect antiglobulin tests (IAT [indirect antiglobulin test]; also called indirect Coombs test) that can mask alloantibodies against donor blood antigens, creating a blood bank compatibility challenge. Before initiating daratumumab, blood typing and antibody screening must be performed (results stored for reference); subsequently, blood bank laboratories must be notified that the patient is receiving daratumumab and special techniques (e.g., dithiothreitol [DTT] treatment of reagent RBCs, or use of daratumumab-insensitive phenotyping methods) must be used for pre-transfusion compatibility testing.
Denosumab: Anti-RANKL in Bone Metastases. Denosumab is a fully human IgG2 mAb that binds RANKL (receptor activator of NF-kB [nuclear factor kappa-B] ligand), preventing RANKL from binding its receptor RANK (receptor activator of NF-kB) on osteoclast precursors and mature osteoclasts.8 By blocking the RANKL (receptor activator of NF-kB ligand)-RANK interaction, denosumab suppresses osteoclast differentiation, activation, and survival, reducing bone resorption and skeletal-related events (SREs [skeletal-related events]) in patients with bone metastases from solid tumors (breast cancer, prostate cancer, lung cancer, and others) and in patients with giant cell tumor of bone (GIST; at a higher dose). Denosumab is administered subcutaneously every 4 weeks; it does not undergo renal elimination (unlike bisphosphonates), making it usable where bisphosphonates are contraindicated.
Denosumab: Hypocalcemia and Osteonecrosis of the Jaw. The critical toxicity in the bone metastasis setting is hypocalcemia, which occurs in approximately 10-18% of patients (grade 3 or higher in 3-5%) and is more common with denosumab than with bisphosphonates due to its more complete osteoclast suppression. Mandatory co-supplementation with calcium (at least 500 mg elemental calcium daily, often 1000-1500 mg) and vitamin D (at least 400 IU daily, often 800-1000 IU) throughout therapy is required to prevent hypocalcemia; patients with pre-existing hypocalcemia must have calcium levels corrected before starting denosumab. Osteonecrosis of the jaw (ONJ) occurs in approximately 1-2% of patients on long-term denosumab for bone metastases; risk factors include dental extractions, poor oral hygiene, denture use, and concurrent corticosteroids. A dental evaluation with completion of any invasive dental procedures before starting denosumab is recommended, and denosumab should be held for dental surgery during therapy.
Daratumumab binds CD38 on red blood cells, causing positive pan-reactive indirect antiglobulin tests that persist for up to 6 months after the last dose. This can mask clinically significant alloantibodies and delay or compromise safe blood transfusion. Before starting daratumumab: (1) perform ABO/Rh typing and antibody screen and inform the blood bank; (2) blood bank must use special techniques (DTT-treated cells or genotyping-based crossmatch) for all future compatibility testing; (3) in emergency transfusion, use compatible least-incompatible units; (4) carry a daratumumab patient identification card. Failure to notify the blood bank before daratumumab initiation can result in inability to detect dangerous alloantibodies in future transfusions.
Antibody-drug conjugates (ADCs) combine the target selectivity of monoclonal antibodies with the cytotoxic potency of small molecule drugs, delivering a chemotherapy payload directly to tumor cells expressing the target antigen while sparing normal tissues. The clinical development of HER2 (human epidermal growth factor receptor 2)-directed ADCs (antibody-drug conjugates) has reshaped breast cancer therapy and introduced pharmacologic concepts, including the HER2-low classification and bystander killing, that are now central to oncologic clinical reasoning.
ADC (Antibody-Drug Conjugate) Structure and Pharmacologic Principles. An ADC consists of three components: a targeting monoclonal antibody, a chemical linker, and a cytotoxic payload (warhead).9 The antibody component confers target specificity, distributes the ADC like a conventional mAb (large-molecule pharmacokinetics, no CYP metabolism), and mediates ADCC (antibody-dependent cellular cytotoxicity) as an additional anti-tumor mechanism. The linker connects antibody to payload and determines the ADC’s stability in circulation and its release mechanism: cleavable linkers (hydrazone, disulfide, or peptide-based) release payload in the tumor microenvironment or within lysosomes after internalization and pH or protease-triggered cleavage; non-cleavable linkers (e.g., thioether bonds) release payload only after complete proteolytic degradation of the antibody inside lysosomes, requiring tumor cell internalization for activity.
The drug-to-antibody ratio (DAR [drug-to-antibody ratio]) defines the average number of payload molecules per antibody; traditional ADCs (trastuzumab emtansine, T-DM1 [trastuzumab emtansine]) have DARs of approximately 3.5; newer ADCs (trastuzumab deruxtecan, T-DXd [trastuzumab deruxtecan]) have DARs of approximately 8. Higher DARs increase potency but also increase off-target toxicity and can reduce antibody stability. Bystander killing is the ability of a released payload to diffuse out of the target cell and kill neighboring cells that may not express the target antigen; this property is most clinically significant with membrane-permeable payloads (topoisomerase I inhibitors such as DXd [deruxtecan]) and contributes to efficacy in tumors with heterogeneous target expression.
Trastuzumab Emtansine (T-DM1): First HER2-Directed ADC. T-DM1 (ado-trastuzumab emtansine) links trastuzumab to emtansine (DM1 [maytansinoid 1]), a potent microtubule polymerization inhibitor, via a non-cleavable thioether linker (SMCC [succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate]) with a DAR of approximately 3.5.9 After HER2-mediated internalization, lysosomal catabolism releases the DM1-lysine metabolite, which then disrupts microtubule dynamics in the target cell; because the linker is non-cleavable and the metabolite is charged and membrane-impermeant, bystander killing is minimal. T-DM1 is approved for HER2-positive metastatic breast cancer after prior trastuzumab and taxane therapy, and as adjuvant therapy for HER2-positive early breast cancer with residual disease after neoadjuvant chemotherapy (KATHERINE trial).
T-DM1 Safety. T-DM1 must not be substituted for trastuzumab; they are distinct drugs with distinct mechanisms and toxicity profiles, and confusion between them has caused fatal medication errors. The primary toxicities of T-DM1 are thrombocytopenia (occurring in approximately 28-31% of patients, grade 3 or higher in 5-13%; the mechanism involves DM1-mediated disruption of platelet microtubule dynamics required for proplatelet formation in megakaryocytes) and hepatotoxicity (elevated transaminases and bilirubin; liver function must be monitored before each cycle). T-DM1 does not cause the alopecia, nausea, or mucositis typical of conventional microtubule agents because its payload is delivered primarily to HER2-expressing tumor cells.
Peripheral neuropathy is also observed, reflecting some off-target DM1 exposure in peripheral nerves.
Trastuzumab Deruxtecan (T-DXd): The HER2-Low Paradigm. T-DXd (fam-trastuzumab deruxtecan-nxki) links trastuzumab to deruxtecan, a topoisomerase I inhibitor payload (a derivative of the camptothecin class), via a tetrapeptide-based cleavable linker, with a high DAR of approximately 8.10 After HER2-mediated internalization, lysosomal cathepsins cleave the linker, releasing DXd (a membrane-permeable topoisomerase I inhibitor) that can diffuse into neighboring cells for bystander killing. The high DAR and membrane-permeable payload with bystander killing produce potent activity even at low levels of HER2 expression, giving rise to the concept of HER2-low breast cancer: tumors with HER2 IHC (immunohistochemistry) 1+ or IHC 2+/FISH-negative (not meeting the historical threshold of IHC 3+ or FISH amplification for HER2-positivity) that were previously considered HER2-negative and treated with standard chemotherapy. The DESTINY-Breast04 (a pivotal randomized trial of T-DXd vs. physician's choice chemotherapy in HER2-low breast cancer) trial demonstrated that T-DXd produces superior progression-free survival (9.9 vs. 5.1 months) and overall survival (23.4 vs. 16.8 months) compared to physician's choice chemotherapy in HER2-low breast cancer, establishing T-DXd as standard of care in this newly defined population.13
T-DXd Interstitial Lung Disease. The most serious toxicity of T-DXd is interstitial lung disease (ILD [interstitial lung disease])/pneumonitis, occurring in approximately 10-15% of patients in early trials (predominantly grades 1-2), with rare fatal cases (grade 5 ILD reported in approximately 2.2% in initial studies); ILD is thought to result from bystander killing of pulmonary epithelial cells by the membrane-permeable DXd payload combined with inflammatory mechanisms. ILD management: grade 1 (asymptomatic, CT [computed tomography] findings only), hold T-DXd; grade 2 (symptomatic, not limiting self-care), hold T-DXd and initiate systemic corticosteroids (prednisolone 1 mg/kg/day); grade 3 or higher (limiting self-care, requiring oxygen or hospitalization), permanently discontinue T-DXd and initiate high-dose IV corticosteroids. Patients should be counseled to report any new respiratory symptoms immediately.
Trastuzumab (Herceptin) and T-DM1 (Kadcyla; ado-trastuzumab emtansine) are distinct drugs with different mechanisms, dosing, toxicity profiles, and indications. They must never be substituted for each other. T-DM1 contains a cytotoxic payload; administering T-DM1 instead of trastuzumab in an early-stage adjuvant setting where trastuzumab is indicated would expose the patient to unnecessary cytotoxic toxicity. Conversely, using trastuzumab where T-DM1 is indicated (e.g., post-neoadjuvant residual disease) withholds a survival benefit. Pharmacy verification of the exact drug name (not just the trastuzumab prefix) is mandatory at every dispensing step.
Beyond the HER2 (human epidermal growth factor receptor 2)-directed ADCs (antibody-drug conjugates), three additional ADCs have transformed the treatment of specific lymphoma subtypes and triple-negative breast cancer, each exploiting a distinct tumor surface antigen and delivering a distinct cytotoxic payload. Understanding the target biology, payload mechanism, and payload-specific toxicity of each agent is essential for clinical management.
Brentuximab Vedotin: CD30 (cluster of differentiation 30)-Directed MMAE (monomethyl auristatin E) ADC (antibody-drug conjugate). Brentuximab vedotin links an anti-CD30 (TNF [tumor necrosis factor] receptor superfamily member 8) IgG1 antibody to MMAE (monomethyl auristatin E), a potent microtubule polymerization inhibitor, via a protease-cleavable valine-citrulline dipeptide linker with a DAR (drug-to-antibody ratio) of approximately 4.11 CD30 is highly expressed on Reed-Sternberg cells in classical Hodgkin lymphoma (cHL [classical Hodgkin lymphoma]) and on tumor cells in systemic anaplastic large cell lymphoma (ALCL [anaplastic large cell lymphoma]), making it an ideal ADC target. After CD30-mediated endocytosis, lysosomal cathepsin B cleaves the valine-citrulline linker, releasing membrane-permeable MMAE into the cell and surrounding tumor microenvironment (bystander killing); MMAE disrupts microtubule polymerization, arresting cells in G2/M (growth 2/mitosis) phase and inducing apoptosis.
Brentuximab vedotin is approved in combination with AVD (doxorubicin, vinblastine, dacarbazine) as first-line therapy for advanced cHL, as consolidation after autologous SCT (stem cell transplant) in cHL at high risk of relapse, in relapsed/refractory cHL and systemic ALCL, and in cutaneous CD30+ T-cell lymphomas. The dose-limiting toxicity is peripheral neuropathy (PN [peripheral neuropathy]), occurring in approximately 56% of patients (sensory predominant), driven by MMAE disruption of axonal microtubule dynamics in dorsal root ganglion neurons; PN is managed identically to bortezomib PN with graded dose modifications. PML (progressive multifocal leukoencephalopathy) has been reported with brentuximab vedotin; patients presenting with new neurological symptoms should be evaluated with brain MRI (magnetic resonance imaging) and CSF (cerebrospinal fluid) JC (John Cunningham) virus PCR (polymerase chain reaction).
Brentuximab Vedotin Drug Interactions. MMAE is metabolized by CYP3A4 (cytochrome P450 3A4); strong CYP3A4 inhibitors (ketoconazole, clarithromycin) increase MMAE exposure; strong inducers (rifampin) reduce exposure. Rifampin increased MMAE AUC (area under the concentration-time curve) by approximately 14%; ketoconazole increased MMAE AUC by approximately 34%.
Polatuzumab Vedotin: MMAE Conjugate Targeting the B-Cell Receptor. Polatuzumab vedotin links an antibody against cluster of differentiation 79b (abbreviated cd79b, also called immunoglobulin-associated beta) to MMAE via the same protease-cleavable valine-citrulline linker used in brentuximab vedotin, with a DAR of approximately 3.5.11 The target, cd79b (also designated immunoglobulin-associated beta, a B-cell receptor [BCR] signaling subunit), is a component of the B-cell receptor (BCR [B-cell receptor]) complex expressed on the surface of mature B cells and most B-cell NHLs (non-Hodgkin lymphomas), including DLBCL (diffuse large B-cell lymphoma). Polatuzumab vedotin is approved in combination with bendamustine and rituximab (pola-BR) for relapsed or refractory DLBCL after at least two prior therapies, and in combination with R-CHP (rituximab, cyclophosphamide, hydroxydaunorubicin, prednisone) as first-line therapy for previously untreated DLBCL (POLARIX trial). Because the payload is the same MMAE as in brentuximab vedotin, the toxicity profile is similar: peripheral neuropathy (PN), myelosuppression (neutropenia, thrombocytopenia), and the same CYP3A4-based drug interactions apply to MMAE release. The addition of polatuzumab vedotin to bendamustine-rituximab significantly improved complete response rates and PFS (progression-free survival) in relapsed/refractory DLBCL compared to bendamustine-rituximab alone; it replaced older salvage chemotherapy regimens (including VNCOP-B [vincristine, mitoxantrone, cyclophosphamide, vincristine, prednisolone, bleomycin]) in this setting.
Sacituzumab Govitecan: TROP-2-Targeted ADC. Sacituzumab govitecan links an anti-TROP-2 (trophoblast cell surface antigen 2) IgG1 antibody to a topoisomerase I inhibitor payload (irinotecan's active metabolite, 7-ethyl-10-hydroxycamptothecin [SN-38]) via a pH-sensitive CL2A (carbonate linker); DAR approximately 7.6.12 TROP-2 is a cell surface glycoprotein overexpressed in multiple solid tumors including triple-negative breast cancer (TNBC [triple-negative breast cancer]), urothelial carcinoma, NSCLC (non-small cell lung cancer), and endometrial cancer. Sacituzumab govitecan is approved for metastatic TNBC after at least two prior therapies (ASCENT [Antibody-Drug Conjugate SN-38 for Triple-Negative Breast Cancer] trial; PFS 5.6 vs. 1.7 months, OS [overall survival] 12.1 vs. 6.7 months vs. physician's choice chemotherapy), HER2-negative hormone receptor-positive metastatic breast cancer after endocrine therapy and chemotherapy, and locally advanced or metastatic urothelial carcinoma after platinum and PD-1/PD-L1 (programmed death-1/programmed death-ligand 1) inhibitor therapy.
Sacituzumab Govitecan: Pharmacogenomics. Sacituzumab govitecan carries a pharmacogenomic drug interaction: SN-38 is generated from irinotecan by carboxylesterase activation and subsequently glucuronidated (detoxified) by UGT1A1 (uridine diphosphate-glucuronosyltransferase 1A1 [UDP-GT1A1]). Patients with UGT1A1*28/*28 homozygous genotype (a TA (thymine-adenine)-repeat polymorphism in the UGT1A1 promoter that reduces UGT1A1 expression, occurring in approximately 10% of patients) are at substantially higher risk of SN-38-related toxicity, particularly severe neutropenia and diarrhea, because they cannot efficiently glucuronidate and eliminate SN-38. UGT1A1 genotyping before initiating sacituzumab govitecan is recommended; UGT1A1*28 homozygous patients may require closer monitoring and earlier dose reduction.
The dominant toxicities of sacituzumab govitecan include neutropenia (approximately 64%, grade 3 or higher in approximately 51%), diarrhea (approximately 65%, grade 3 or higher in approximately 10%), nausea, and fatigue, reflecting the SN-38 payload mechanism and qualitatively resembling but exceeding irinotecan toxicity.
ADC Class Toxicities and Monitoring Framework. Despite their diverse targets and payloads, ADCs share several class-level clinical management principles. Infusion-related reactions (IRRs [infusion-related reactions]) occur with all ADCs during the first one to two infusions, reflecting immune recognition of the antibody component; pre-medication with antihistamines and corticosteroids is standard, and infusion rates must be slowed or stopped for grade 2 or higher reactions. Myelosuppression, particularly neutropenia, is a common toxicity across ADCs whose payloads include microtubule inhibitors (MMAE) or topoisomerase inhibitors (SN-38, DXd); CBC (complete blood count) monitoring before each cycle and growth factor support (G-CSF [granulocyte colony-stimulating factor]) for grade 3 or higher neutropenia are standard. Peripheral neuropathy is specifically associated with MMAE-containing ADCs (brentuximab vedotin, polatuzumab vedotin) due to axonal microtubule disruption; it is not expected with SN-38 or DXd payloads. Extravasation of ADCs during IV infusion can cause significant local tissue damage; central venous access is preferred when feasible. Pregnancy exposure to ADCs is contraindicated because both the antibody component (which crosses the placenta in the second and third trimesters via FcRn) and the cytotoxic payload can cause fetal harm; highly effective contraception is mandatory during therapy and for at least 7 months (brentuximab vedotin), 3 months (sacituzumab govitecan), or 7 months (T-DXd) after the last dose for women of childbearing potential.
Patients homozygous for UGT1A1*28 (also written UGT1A1*28/*28; sometimes detected by genotype report as TA7/TA7 or 7/7 in the UGT1A1 promoter TA repeat) have approximately 30-50% reduced UGT1A1 activity compared to wild-type patients, impairing SN-38 glucuronidation. In irinotecan-treated patients, UGT1A1*28 homozygosity predicts severe neutropenia and diarrhea. The same pharmacogenomic risk applies to sacituzumab govitecan given the identical SN-38 payload. UGT1A1 genotyping is recommended before treatment; if homozygous, consider initiating at the lower end of the tolerated dose range and increasing frequency of toxicity monitoring. Heterozygous patients (UGT1A1*1/*28) are at intermediate risk and generally can receive standard doses with standard monitoring.
Monoclonal antibodies and ADCs are encountered across inpatient and outpatient settings as the treating oncologist, internist, hospitalist, and specialist must manage their toxicities, drug interactions, and contraindication profiles. This section maps the highest-yield clinical decision points for this drug class to practical clinical action.
HER2 (Human Epidermal Growth Factor Receptor 2) Testing and Therapy Selection. HER2 overexpression or amplification is the biomarker that gates trastuzumab, pertuzumab, T-DM1, and T-DXd (in HER2-positive disease) eligibility. Standard HER2 testing uses IHC (immunohistochemistry) as the initial screen: IHC 3+ (uniform strong staining in more than 10% of invasive tumor cells) is HER2-positive; IHC 0 or IHC 1+ is HER2-negative by historical criteria; IHC 2+ requires FISH (fluorescence in situ hybridization) confirmation.3 For the T-DXd HER2-low indication, a fourth category has been defined: IHC 1+ or IHC 2+/FISH-negative constitutes HER2-low, which is now a distinct therapeutic biomarker for T-DXd eligibility in hormone receptor-positive metastatic breast cancer after endocrine therapy and in TNBC (triple-negative breast cancer) after chemotherapy. This reclassification means that approximately 55-60% of previously HER2-negative breast cancers are now HER2-low and potentially eligible for T-DXd, representing a major expansion of the treatable population. FISH (fluorescence in situ hybridization) remains the gold standard for HER2 gene amplification; NGS (next-generation sequencing)-based HER2 copy number assessment is increasingly available as a reflex test.
Managing Bevacizumab in the Perioperative and Comorbid Setting. The 28-day pre- and post-operative hold for bevacizumab is the most frequently tested perioperative pharmacology rule for mAbs. Additional important management scenarios include: (1) bevacizumab in patients with proteinuria from pre-existing renal disease or diabetic nephropathy requires baseline 24-hour urine protein quantification and close monitoring, as the drug substantially worsens proteinuria; (2) bevacizumab is contraindicated in patients with recent arterial thromboembolic events (myocardial infarction [MI], stroke) within 6 months; (3) bevacizumab in combination with platinum-based chemotherapy for NSCLC (non-small cell lung cancer) is contraindicated in squamous cell histology due to catastrophic hemoptysis from tumor cavitation (the pivotal ECOG (Eastern Cooperative Oncology Group) 4599 trial excluded squamous cell histology for this reason); (4) hypertension management during bevacizumab therapy should use renin-angiotensin system agents or dihydropyridine calcium channel blockers; avoid beta-blockers as monotherapy since they may mask symptoms of bevacizumab-associated PRES (posterior reversible encephalopathy syndrome).4
Infusion Reaction Management Across mAbs and ADCs. Infusion-related reactions (IRRs) are the most common acute complication of mAb (monoclonal antibody) and ADC (antibody-drug conjugate) administration, occurring most frequently during the first infusion when the patient’s immune system has not previously encountered the antibody. The vast majority of IRRs are cytokine release reactions (fever, chills, rigors, flushing, hypotension, dyspnea) rather than IgE-mediated anaphylaxis; they typically occur within the first 30-60 minutes of infusion and are managed by stopping or slowing the infusion, administering IV corticosteroids and antihistamines, and resuming at a slower rate after symptom resolution. Grade 1-2 IRRs generally do not preclude future infusions with enhanced pre-medication; grade 3 IRRs require evaluation for rechallenge on a case-by-case basis; grade 4 IRRs (anaphylaxis, life-threatening bronchospasm) result in permanent discontinuation. Pre-medication protocols vary by agent: obinutuzumab and rituximab require corticosteroids, antihistamines, and acetaminophen; cetuximab requires antihistamines (with high-dose diphenhydramine, 50 mg IV) given the risk of alpha-gal IgE-mediated reactions; daratumumab requires dexamethasone, antihistamines, acetaminophen, and a leukotriene modifier (montelukast) for the first infusions.67
Mutation Testing Required Before Anti-EGFR Prescribing. RAS (rat sarcoma viral proto-oncogene) wild-type status before prescribing cetuximab or panitumumab in colorectal cancer is a companion diagnostic mandate. Any KRAS (Kirsten rat sarcoma viral proto-oncogene) or NRAS (neuroblastoma RAS viral proto-oncogene) mutation (exons 2, 3, or 4 for both genes) predicts lack of benefit and mandates exclusion from anti-EGFR therapy. Prescribing anti-EGFR antibodies in RAS (rat sarcoma viral proto-oncogene)-mutant colorectal cancer is a prescribing error; it exposes patients to significant toxicity (rash, hypomagnesemia, infusion reactions) without clinical benefit. Additionally, primary tumor sidedness now informs anti-EGFR selection independent of RAS status: left-sided (splenic flexure to rectum) RAS/BRAF (v-raf murine sarcoma viral oncogene homolog B)-wild-type mCRC benefits substantially from anti-EGFR therapy; right-sided (cecum to splenic flexure) mCRC has substantially lower benefit from anti-EGFR antibodies, and bevacizumab-based regimens are preferred in that setting regardless of RAS status.5
Special Populations: Pregnancy, HBV (Hepatitis B Virus) Prophylaxis, and Immunization. All mAbs cross the placenta in the second and third trimesters via FcRn-mediated transport, with potential effects on fetal development including fetal B-cell depletion (rituximab), suppression of fetal immune maturation (daratumumab), and fetal HER2 signaling disruption (trastuzumab, pertuzumab). Most therapeutic mAbs are classified as harmful to the fetus and require effective contraception during and for defined periods after therapy. HBV screening (HBsAg and HBcAb) is mandatory before all anti-CD20 (rituximab, obinutuzumab) and anti-CD38 (daratumumab) therapies, and increasingly recommended before any biologic that produces significant B-cell depletion. Inactivated influenza and pneumococcal vaccines should be administered before anti-CD20 therapy if possible, as rituximab-mediated B-cell depletion abolishes the vaccine response for 6-9 months. Live vaccines are absolutely contraindicated in patients receiving rituximab or any other immunosuppressive mAb; the attenuated vaccine strain can cause disseminated infection in B-cell-depleted patients.6
HER2-positive breast cancer patient starting adjuvant AC-T (doxorubicin-cyclophosphamide followed by paclitaxel) then trastuzumab: confirm that trastuzumab does not begin until the last anthracycline dose is complete; concurrent use is contraindicated. Bevacizumab-treated colorectal cancer patient scheduled for colostomy reversal: hold bevacizumab at least 28 days before surgery; do not resume until wound healing is complete (at least 28 days after surgery). Cetuximab candidate with mCRC: confirm complete RAS testing (KRAS and NRAS exons 2, 3, 4) and BRAF V600E is wild-type before prescribing; confirm left-sided primary tumor. Patient starting daratumumab: notify blood bank before first dose; patient requires DTT-treated crossmatch for all future blood transfusions. T-DXd-treated patient presents with new dyspnea and ground-glass opacities on CT: hold T-DXd immediately; evaluate for ILD grade; initiate corticosteroids for grade 2 or higher; grade 3-5 ILD requires permanent discontinuation. Sacituzumab govitecan candidate: consider UGT1A1 genotyping; if UGT1A1*28 homozygous, anticipate higher neutropenia/diarrhea risk and plan enhanced monitoring. Patient on rituximab presents with progressive neurological symptoms: evaluate for PML with brain MRI and CSF JC virus PCR; if confirmed, permanently discontinue rituximab and initiate supportive care.
Ryman JT, Meibohm B. Pharmacokinetics of monoclonal antibodies. CPT Pharmacometrics Syst Pharmacol. 2017;6(9):576-588.
doi:10.1002/psp4.12224Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJ. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov. 2010;9(4):325-338.
doi:10.1038/nrd3003Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783-792.
doi:10.1056/NEJM200103153441101Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335-2342.
doi:10.1056/NEJMoa032691Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360(14):1408-1417.
doi:10.1056/NEJMoa0805019Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235-242.
doi:10.1056/NEJMoa011795Lonial S, Weiss BM, Usmani SZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016;387(10027):1551-1560.
doi:10.1016/S0140-6736(15)01120-4Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28(35):5132-5139.
doi:10.1200/JCO.2010.29.7101Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783-1791.
doi:10.1056/NEJMoa1209124Modi S, Saura C, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382(7):610-621.
doi:10.1056/NEJMoa1914510Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin lymphoma. J Clin Oncol. 2012;30(18):2183-2189.
doi:10.1200/JCO.2011.38.0410Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384(16):1529-1541.
doi:10.1056/NEJMoa2028485Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387(1):9-20.
doi:10.1056/NEJMoa2203690